David Happel
Known title: President & CEOCIK: 0001623567
David Happel's purchase track record
How the stock did after each of David Happel's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
3
of 3 since November 16, 2023
Stock higher 6 months later
67%
3 months: 67%
Median 6-month return
+15.1%
3 months: +59.7%
Beat the S&P 500
33%
median -1.6% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 3/26/2024 | SGMT | $64K | -20.8% | -45.3% | +10.2% |
| 12/7/2023 | SGMT | $7K | +59.7% | +15.1% | +16.7% |
| 11/16/2023 | SGMT | $1K | +271.7% | +103.9% | +17.5% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| SGMT | ▼ Sell | Open Market | 64,051 | $497K | 7/20/2026 | View on chart |
| SGMT | ▲ Buy | Grant | 128,000 | $0 | 2/19/2026 | View on chart |
| SGMT | ▼ Sell | Open Market | 12,101 | $65K | 2/10/2026 | View on chart |
| SGMT | ▼ Sell | Open Market | 65,478 | $598K | 7/21/2025 | View on chart |
| SGMT | ▲ Buy | Grant | 116,000 | $0 | 2/6/2025 | View on chart |
| SGMT | ▲ Buy | Open Market | 12,100 | $64K | 3/26/2024 | View on chart |
| SGMT | ▲ Buy | Open Market | 1,600 | $7K | 12/7/2023 | View on chart |
| SGMT | ▲ Buy | Grant | 624,910 | $0 | 11/17/2023 | View on chart |
| SGMT | ▲ Buy | Open Market | 590 | $1K | 11/16/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Goldman Sachs reinstates Sell rating on SGMT with $7 target
Goldman Sachs has reinstated a Sell rating on Sagimet Biosciences, setting a price target of $7. This move stands in contrast to the average analyst target of $29.60, highlighting a significant divergence in expert opinions. The stock is currently trading near its 52-week low of $4.50, reflecting the bearish sentiment associated with the new rating.
Goldman Sachs reinstates Sell rating on SGMT with $7 target. Goldman Sachs has reinstated a Sell rating on Sagimet Biosciences, setting a price target of $7. This move stands in contrast to the average analyst target of $29.60, highlighting a significant divergence in expert opinions. The stock is currently trading near its 52-week low of $4.50, reflecting the bearish sentiment associated with the new rating.